Mostrando 2 resultados de: 2
A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients
ArticleAbstract: Purpose: EGFR is a well-validated target for patients with non-small cell lung cancer (NSCLC). CIMAvPalabras claves:Autores:Acosta S.C., Aguilera N., Alonso L., Amador R.M., Arzuaga L., Cala M., Carmen Elena Viada, Catala M., Crespo T., De La Torre A.V., Fleytas R., Flores Y.I., Futiel N., García Verdecia B., Lage Davila A., Luaces P.L.o., Marrero Miragaya M.A., Martínez O., Mazorra Z., Mendoza S., Neninger Vinageras E., Otero Y., Parra J., Pomares Y., Popa X., Reyes D., Rodríguez G., Rodríguez P.C., Romero G.N., Sabates T., Santiesteban E.R., Sierra P., Tania Crombet, Vello L.Fuentes:scopusPhase i/ii clinical trial of the humanized anti-egf-r monoclonal antibody h-r3 labelled with <sup>99m</sup>tc in patients with tumour of epithelial origin
ArticleAbstract: To evaluate the biodistribution, internal radiation dosimetry and toxicity of the humanized MAb h-R3Palabras claves:biodistribution, Dosimetry, Humanized MAb, RadioimmunodiagnosisAutores:Aguilar V., Batista J.F., Coca M.A., Hernández A., Iznaga-Escobar N., Neninger Vinageras E., Perera A., Pérez M., Ramos M., Romero S., Sánchez E., Tania Crombet, Torres L.Fuentes:scopus